peptide analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
== Initiatives around the globe == In the United States in 2006, JDRF (formerly the Juvenile Diabetes Research Foundation) launched a multi-year initiative to help accelerate the development, regulatory approval, and acceptance of continuous glucose monitoring and artificial pancreas technology. Grassroots efforts to create and commercialize a fully automated artificial pancreas system have also arisen directly from patient advocates and the diabetes community. In April 2024, the NHS announced it would, over the next five years, offer use of a Hybrid Closed Loop system to Type 1 diabetes patients in England.
=== Phase 1 === AH-001 – topical – alopecia – ubiquitin-protein ligase expression stimulant AMP-303 – intradermal – alopecia – undefined mechanism of action (polysaccharide) CKD-843 – oral, injection – alopecia – undefined mechanism of action CKR-051 – transdermal – alopecia – CXXC5 protein inhibitor, Wnt signalling pathway stimulant DR-01 – parenteral – alopecia areata – antibody-dependent cell cytotoxicity, T lymphocyte stimulant ET-02 (RS-5441) – topical – alopecia, hair disorders – undefined mechanism of action (targets and restores hair follicle stem cells) FOL-100 – topical – alopecia – undefined mechanism of action OLX-72021 – intradermal injection – alopecia – RNA interference QY-201 – oral – alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor SCO-240 – oral – alopecia – somatostatin receptor 5 modulator Squaric acid dibutyl ester (SQX-770) – topical – alopecia areata – immunomodulator VDAA – topical – alopecia areata – undefined mechanism of action
Circulating levels of 0.6 ng/mL with 2% solution and 1.6 ng/mL with 5% solution occur with topical minoxidil. However, levels vary between individuals, with a range of undetectable to 7.5 ng/mL with 3% solution in 12 individuals in one study. Significant cardiological and hemodynamic effects are said to occur with minoxidil when serum minoxidil levels exceed 20 ng/mL.
Sources: en.wikipedia.org
=== Viral infections === Increased blood CRP levels were higher in people with avian flu H7N9 compared to those with H1N1 (more common) influenza, with a review reporting that severe H1N1 influenza had elevated CRP. In 2020, people infected with COVID-19 in Wuhan, China, had elevated CRP.
== Business model and operations == Seer receives revenue from the sale of products to government, academic, biopharma, and contract research organization (CRO) customers, and by providing proteomics services through its Seer Technology Access Center (STAC) in Redwood City and Bonn, Germany. Seer has approximately 140 employees, including sales and customer support staff in the USA, Europe, and Asia. The company’s headquarters, including its research and development, is located in Redwood City, California, with additional offices in San Diego, California, and a services laboratory in Bonn, Germany. The company generated $14.2 million of revenue in 2024.
==== Absorption ==== The intestinal absorption of ritonavir requires an aqueous solubility threshold of greater than 1–2 µg/mL, which the drug achieves via an N-methylurea linker that allows it to be formulated for oral administration. The absolute bioavailability in humans has not been definitively established, though animal models indicate an absolute bioavailability between 74% and 76.4%.
It can be attributed to the first pass through the liver with oral administration and to the high oral bioavailability and strong resistance to hepatic metabolism of these agents. Enobosarm has no estrogenic activity, either intrinsic to itself or via its metabolites. As a result, the drug is not expected to have feminizing effects or risk of gynecomastia (breast development) nor to stimulate estrogen-sensitive breast cancer. SARMs like enobosarm are not ideal agents for androgen replacement therapy as they are not expected to reproduce the full spectrum of effects of testosterone and other androgens, including not only AR-mediated effects but also notably aromatization into estrogen and required physiological estrogenic effects in bone and brain. Enobosarm has been found to be a weak antagonist of the progesterone receptor and hence might have some capacity for antiprogestogenic effects. Aside from its weak interaction with the progesterone receptor, enobosarm is highly selective for the AR and does not bind to other nuclear hormone receptors.
Sources: en.wikipedia.org
== States == It was the individual states that formed the Federal Republic of Germany in 1949. This contrasted with post-war developments in Austria, where the national federation (Bund) was established first, and the individual states were subsequently defined as units within that federal framework. The German use of the term Länder ("lands") dates back to the Weimar Constitution of 1919. Previously, the states of the German Empire had been called Staaten ("states"). Today, it is common to use the term Bundesland (federated Land). Officially, the term "Bundesland" appears in neither the 1919 constitution nor the current one. Three Länder call themselves Freistaaten ("free states", an older German term for "republic"): Bavaria (since 1919), Saxony (originally from 1919 and again since 1990), and Thuringia (since 1994). Of the 17 states at the end of the Weimar Republic, six still exist (though partly with different borders):
Humans have known about the heart since ancient times, although its precise function and anatomy were not clearly understood. From the primarily religious views of earlier societies towards the heart, ancient Greeks are considered to have been the primary seat of scientific understanding of the heart in the ancient world. Aristotle considered the heart to be the organ responsible for creating blood; Plato considered the heart as the source of circulating blood and Hippocrates noted blood circulating cyclically from the body through the heart to the lungs. Erasistratos (304–250 BCE) noted the heart as a pump, causing dilation of blood vessels, and noted that arteries and veins both radiate from the heart, becoming progressively smaller with distance, although he believed they were filled with air and not blood. He also discovered the heart valves. The Greek physician Galen (2nd century CE) knew blood vessels carried blood and identified venous (dark red) and arterial (brighter and thinner) blood, each with distinct and separate functions. Galen, noting the heart as the hottest organ in the body, concluded that it provided heat to the body. The heart did not pump blood around, the heart's motion sucked blood in during diastole and the blood moved by the pulsation of the arteries themselves. Galen believed the arterial blood was created by venous blood passing from the left ventricle to the right through 'pores' between the ventricles. Air from the lungs passed from the lungs via the pulmonary artery to the left side of the heart and created arterial blood.
== History == In December 2008, the US Food and Drug Administration (FDA) approved degarelix for the treatment of people with advanced prostate cancer. It was subsequently approved by the European Commission at the recommendation of the European Medicines Agency (EMA) in February 2009, for use in adult males with advanced, hormone-dependent prostate cancer. Ferring Pharmaceuticals markets the drug under the name Firmagon.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.